Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Arrowhead Pharmaceuticals Inc. currently has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners, ensuring a diverse range of perspectives across the pending applications. The prosecution spans 4 distinct art units, which indicates that the company's biotechnological research is categorized into several specialized technical groups at the patent office.
The busiest examiner, ORWIG, KEVIN S, is handling 1 pending office action. Since each of the 5 pending office actions is managed by a different examiner, no single individual has a disproportionate impact on the portfolio. Practitioners should note that the ratio of 5 distinct examiners to 4 distinct art units suggests that most examiners are working within their own specific technical units. This distribution requires a flexible prosecution strategy that can adapt to the unique requirements of 5 different examiners across multiple specialized fields.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORWIG, KEVIN S | 1 | 25.5% | +40.1% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18181311 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SULLIVAN, STEPHANIE LAUREN | 12d |
| 18653842 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF HEPATITIS B VIRUS | ORWIG, KEVIN S | — |
| 18178179 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | DACE DENITO, ALEXANDRA GERALDINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18181311 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SULLIVAN, STEPHANIE LAUREN | 12d |
| 18653842 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF HEPATITIS B VIRUS | ORWIG, KEVIN S | — |
| 18181335 | Skeletal Muscle Delivery Platforms and Methods of Use | VYAS, KEYUR ANILKUMAR | — |
| 18178179 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | DACE DENITO, ALEXANDRA GERALDINE | — |
| 18160114 | INTEGRIN LIGANDS AND USES THEREOF | VANHORN, ABIGAIL LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 3991 | 1 |
| 1635 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18653842 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF HEPATITIS B VIRUS | ORWIG, KEVIN S | 3991 | Other | Non-Final OA | — | Pending | May 02, 2024 |
| 18181311 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112Other | Final Rejection | 12d | Pending | Mar 09, 2023 |
| 18181335 | Skeletal Muscle Delivery Platforms and Methods of Use | VYAS, KEYUR ANILKUMAR | 1637 | §102§103DP | Non-Final OA | — | Pending | Mar 09, 2023 |
| 18178179 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §102§103§112Other | Non-Final OA | — | Pending | Mar 03, 2023 |
| 18160114 | INTEGRIN LIGANDS AND USES THEREOF | VANHORN, ABIGAIL LOUISE | 1636 | §103DP | Non-Final OA | — | Pending | Jan 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArrowhead Pharmaceuticals Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Kevin S Orwig has the most, with 1 of Arrowhead Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.